Medindia

X

Drugs for Treatment of Prostate Cancer-China, Russia, Brazil and Japan Research Report 2015 to 2021

Thursday, June 16, 2016 Drug News J E 4
Advertisement

PUNE, India, June 15, 2016 /PRNewswire-iReach/ -- ACCESS REPORT

The global Drugs for Treatment of Prostate Cancer market was valued at USD 30.41 Billion in 2015, and is projected to reach USD 35.26 Billion by 2021, at a CAGR of 59.49% between 2016 and 2021. The market is projected witness significant growth in the coming years, owing to the aging population increase, increased incidence and development of new drugs

Photo - http://photos.prnewswire.com/prnh/20160615/379518

This report studies Drugs for Treatment of Prostate Cancer in China, Russia, Brazil and Japan market, including Triptorelin, Leuprorelin, Flutamide Tablets, Goserelin, Bicalutamide Tablets, Bicalutamide Capsules, Estramustine Phosphate Capsules, Mitoxantrone, Zytiga and Xtandi, focuses on price, sales, revenue of each type in global. This report also focuses on the sales (consumption), production, import and export of Drugs for Treatment of Prostate Cancer forecast to 2021, from 2015. 

On basis of segments by Types, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers.

On basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Drugs for Treatment of Prostate Cancer, revenue and market share, for key manufacturers. The main manufacturers as follows: IPSEN, Ferring Pharmaceuticals, Takeda Pharmaceutical Company Limited, Schering-Plough Canada, S.C.SINDAN-PHARMA S.R.L., AstraZeneca, Corden Pharma GmbH, Shanxi Zhendong Pharmaceutical, Pfizer, Johnson, Astellas and so on.

On basis of segments by regions, this report focuses on the sales (consumption), production, import and export of Drugs for Treatment of Prostate Cancer in America, Established ROW, Western Europe, Emerging Markets, Russia and China.

On basis of segments by applications, this report focuses on consumption and growth rate of Drugs for Treatment of Prostate Cancer in major applications.

With 220ges, 231 charts and eight chapters, to display the market present situation and future, clearly and deeply.

AVAIL SAMPLE REPORT

COMPANIES MENTIONED :

6 Key Manufacturers Analysis of Drugs for Treatment of Prostate Cancer 

    6.1 IPSEN 

      6.1.1 IPSEN Basic Information 

      6.2.2 Triptorelin (Specification and Price) 

      6.2.3 Sales Value, Gross Margin 2011-2016 

      6.1.4 Interviewee, Name and Contact 

    6.2 Ferring Pharmaceuticals 

      6.2.1 Company Basic Information 

      6.2.2 Triptorelin (Specification and Price) 

      6.2.3 Sales Value, Gross Margin 2011-2016 

      6.2.4 Interviewee, Name and Contact 

    6.3 Chengdu Tiantaishan pharmaceutical 

      6.3.1 Company Basic Information 

      6.3.2 Triptorelin (Specification and Price) 

      6.3.3 Sales Value, Gross Margin 2011-2016 

      6.3.4 Interviewee, Name and Contact 

    6.4 GeneScience Pharmaceuticals 

      6.4.1 Company Basic Information 

      6.4.2 Triptorelin (Specification and Price) 

      6.4.3 Sales Value, Gross Margin 2011-2016 

      6.4.4 Interviewee, Name and Contact 

    6.5 Takeda Pharmaceutical Company Limited 

      6.5.1 Company Basic Information 

      6.5.2 Leuprorelin (Specification and Price) 

      6.5.3 Sales Value, Gross Margin 2011-2016 

      6.5.4 Interviewee, Name and Contact 

    6.6 Beijing Biote Pharmaceutical 

      6.6.1 Company Basic Information 

      6.6.2 Leuprorelin (Specification and Price) 

      6.6.3 Sales Value, Gross Margin 2011-2016 

      6.6.4 Interviewee, Name and Contact 

    6.7 Livzon Pharmaceutical Group 

      6.7.1 Company Basic Information 

      6.7.2 Leuprorelin (Specification and Price) 

      6.7.3 Sales Value, Gross Margin 2011-2016 

      6.7.4 Interviewee, Name and Contact 

    6.8 Schering-Plough Canada 

      6.8.1 Company Basic Information 

      6.8.2 Flutamide Tablets (Specification and Price) 

      6.8.3 Sales Value, Gross Margin 2011-2016 

      6.8.3 Sales Value, Gross Margin 2011-2016 

      6.8.3 Sales Value, Gross Margin 2011-2016 

      6.8.3 Sales Value, Gross Margin 2011-2016 

      6.8.4 Interviewee, Name and Contact 

6. 9 JiangSu TASLY DI YI Pharmaceutical 

      6.9.1 Company Basic Information 

      6.9.2 Flutamide Tablets (Specification and Price) 

      6.9.3 Sales Value, Gross Margin 2011-2016 

      6.9.4 Interviewee, Name and Contact 

    6.10 Shanghai Fudan Fuhua Pharmaceutical 

      6.10.1 Company Basic Information 

      6.10.2 Flutamide Tablets (Specification and Price) 

      6.10.3 Sales Value, Gross Margin 2011-2016 

      6.10.4 Interviewee, Name and Contact 

    6.11 S.C.SINDAN-PHARMA S.R.L. 

      6.11.1 Company Basic Information 

      6.11.2 Flutamide Tablets (Specification and Price) 

      6.11.3 Sales Value, Gross Margin 2011-2016 

      6.11.4 Interviewee, Name and Contact 

    6.12 AstraZeneca 

      6.12.1 Company Basic Information 

      6.12.2 Goserelin (Specification and Price) 

      6.12.3 Sales Value, Gross Margin 2011-2016 

      6.12.4 Interviewee, Name and Contact 

    6.13 Corden Pharma GmbH 

      6.13.1 Company Basic Information 

      6.13.2 Bicalutamide Tablets (Specification and Price) 

      6.13.3 Sales Value, Gross Margin 2011-2016 

      6.13.4 Interviewee, Name and Contact 

    6.14 Shanghai Zhaohui Pharmaceutical 

      6.14.1 Company Basic Information 

      6.14.2 Bicalutamide Tablets (Specification and Price) 

      6.14.3 Sales Value, Gross Margin 2011-2016 

      6.14.4 Interviewee, Name and Contact 

    6.15 HISUN Pharmaceutical 

      6.15.1 Company Basic Information 

      6.15.2 Bicalutamide Tablets (Specification and Price) 

      6.15.3 Sales Value, Gross Margin 2011-2016 

      6.15.4 Interviewee, Name and Contact 

    6.16 Shanxi Zhendong Pharmaceutical 

      6.16.1 Company Basic Information 

      6.16.2 Bicalutamide Capsules (Specification and Price) 

      6.16.3 Sales Value, Gross Margin 2011-2016 

      6.16.4 Interviewee, Name and Contact 

    6.17 Pfizer 

      6.17.1 Company Basic Information 

      6.17.2 Estramustine Phosphate Capsules (Specification and Price) 

      6.17.3 Sales Value, Gross Margin 2011-2016 

      6.17.4 Interviewee, Name and Contact 

    6.18 Sichuan sunnyhope pharmaceutical 

      6.18.1 Company Basic Information 

      6.18.2 Mitoxantrone (Specification and Price) 

      6.18.3 Sales Value, Gross Margin 2011-2016 

      6.18.4 Interviewee, Name and Contact 

    6.19 Luoxin Group 

      6.19.1 Company Basic Information 

      6.19.2 Mitoxantrone (Specification and Price) 

      6.19.3 Sales Value, Gross Margin 2011-2016 

      6.19.4 Interviewee, Name and Contact 

    6.20 Jiangsu Aosaikang Pharmaceutical 

      6.20.1 Company Basic Information 

      6.20.2 Mitoxantrone (Specification and Price) 

      6.20.3 Sales Value, Gross Margin 2011-2016 

      6.20.4 Interviewee, Name and Contact 

    6.21 JIANG SU HENG RUI MEDICINE 

      6.21.1 Company Basic Information 

      6.21.2 Mitoxantrone (Specification and Price) 

      6.21.3 Sales Value, Gross Margin 2011-2016 

      6.21.4 Interviewee, Name and Contact 

    6.22 Johnson 

      6.22.1 Company Basic Information 

      6.22.2 Zytiga (Specification and Price) 

      6.22.3 Sales Value, Gross Margin 2011-2016 

      6.22.4 Interviewee, Name and Contact 

    6.23 Astellas 

      6.23.1 Company Basic Information 

      6.23.2 Xtandi (Specification and Price) 

      6.23.3 Sales Value, Gross Margin 2011-2016 

      6.23.4 Interviewee, Name and Contact

…. CONTINUED

GET EXCLUSIVE DISCOUNT ON THIS REPORT

Media Contact: Norah Trent, WiseGuy Reports, +1 646 845 9349, sales@wiseguyreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WiseGuy Reports

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Low Carb USA Asks "Is Our Government's Dietary Adv...
S
Global Prenatal Vitamin Supplements Market 2016-20...